AASCIT - Journal - All Issues

ISSN: 2375-3838

International Journal of Clinical Medicine Research

The Journal

Manuscript Information

Lactoferrin and Necrotizing Enterocolitis in Preterm Infants

International Journal of Clinical Medicine Research
Vol.3 , No. 3, Publication Date: Jun. 7, 2016, Page: 60-63

2265 Views Since June 7, 2016, 1247 Downloads Since Jun. 7, 2016

Paper in PDF (225K)

Paper in Html

Follow on

Authors

[1]	Xiangyong Kong, Newborn Care Center, Bayi Children’s Hospital, Land Force General Hospital of P. L. A., Beijing, China; Clinical Medical College, Land Force General Hospital, Southern Medical University, Beijing, China.
[2]	Zhichun Feng, Newborn Care Center, Bayi Children’s Hospital, Land Force General Hospital of P. L. A., Beijing, China; Clinical Medical College, Land Force General Hospital, Southern Medical University, Beijing, China.

Abstract

Neonatal necrotizing enterocolitis (NEC) is the most important neonatal problem in nursery which is associated with high neonatal mortality and morbidity. NEC also leads to various long term complications, including short bowel syndrome, systemic infection, eye problems, nutritional deficiency and neurodevelopmental impairments. Lactoferrin (LF) is a component of breast milk and multiple actions that includes antimicrobial, antiviral, anti-fungal, enhance immunity and various other actions. A few studies have been completed and a number of trails are going on for evaluation of efficacy and safety of LF in the prevention of NEC. In future, LF prophylaxis and therapy may have a significant impact in improving clinical outcomes of vulnerable premature infants. This review analyse the role of LF in prevention and reduction severity of NEC in preterm infants, with emphasis on mechanism of action, recent studies and current studies going on all over the world.

Keywords

Lactoferrin, Necrotizing Enterocolitis, Preterm Neonates

Reference

[01]	Lim JC, Golden JM, Ford HR. Pathogenesis of neonatal necrotizing enterocolitis. Pediatr Surg Int. 2015; 31: 509-18.
[02]	Christensen RD, Lambert DK, Baer VL, Gordon PV. Necrotizing enterocolitis in term infants. Clin Perinatol. 2013; 40: 69–78.
[03]	Fitzgibbons SC, Ching Y, Yu D, Carpenter J, Kenny M, Weldon C, et al. Mortality of necrotizing enterocolitis expressed by birth weight categories. J Pediatr Surg. 2009; 44: 1072–5.
[04]	Wadhawan R, Oh W, Hintz SR, Blakely ML, Das A, Bell EF, et al; NICHD Neonatal Research Network. Neurodevelopmental outcomes of extremely low birth weight infants with spontaneous intestinal perforation or surgical necrotizing enterocolitis. J Perinatol. 2014; 34: 64-70.
[05]	Patel RM, Denning PW. Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what is the current evidence? Clin Perinatol. 2013; 40: 11-25.
[06]	Sherman MP, Miller MM, Sherman J, Niklas V. Lactoferrin and necrotizing enterocolitis. Curr Opin Pediatr. 2014; 26: 146-50.
[07]	Ramani M, Ambalavanan N. Feeding practices and necrotizing enterocolitis. Clin Perinatol. 2013; 40: 1-10.
[08]	Goldman AS. The immune system in human milk and the developing infant. Breastfeed Med. 2007; 2: 195-204.
[09]	Brock JH. Lactoferrin--50 years on. Biochem Cell Biol. 2012; 90: 245-51.
[10]	Vogel HJ. Lactoferrin, a bird's eye view. Biochem Cell Biol. 2012; 90: 233-44.
[11]	Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin supplementation for prevention of lateonset sepsis in very low-birth-weight neonates: a randomized trial. JAMA. 2009; 302: 1421-8.
[12]	Kaur G, Gathwala G. Efficacy of Bovine Lactoferrin Supplementation in Preventing Late-onset Sepsis in low Birth Weight Neonates: A Randomized Placebo-Controlled Clinical Trial. J Trop Pediatr. 2015; 61: 370-6.
[13]	Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2015; 2: CD007137.
[14]	Ronayne de Ferrer PA, Baroni A, Sambucetti ME, López NE, Ceriani Cernadas JM. Lactoferrin levels in term and preterm milk. J Am Coll Nutr. 2000; 19: 370-3.
[15]	Gonzalez-Chavez SA, Arevalo-Gallegos S, Rascon-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents. 2009; 33: e1-8.
[16]	Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. 2012; 129: e40-5.
[17]	Murata M, Wakabayashi H, Yamauchi K, Abe F. Identification of milk proteins enhancing the antimicrobial activity of lactoferrin and lactoferricin. J Dairy Sci. 2013; 96: 4891-8.
[18]	Kuwata H, Yamauchi K, Teraguchi S, Ushida Y, Shimokawa Y, Toida T, et al. Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats. J Nutr. 2001; 131: 2121-7.
[19]	Patel AL, Trivedi S, Bhandari NP, Ruf A, Scala CM, Witowitch G, et al. Reducing necrotizing enterocolitis in very low birth weight infants using quality-improvement methods. J Perinatol. 2014; 34: 850-7.
[20]	Sherman MP, Adamkin DH, Radmacher PG, Sherman J, Niklas V. Protective Proteins in Mammalian Milks: Lactoferrin Steps Forward. Neoreviews. 2012; 13: e293-e300.
[21]	Oda H, Wakabayashi H, Yamauchi K, Abe F. Lactoferrin and bifidobacteria. Biometals. 2014; 27: 915-22.
[22]	Hu W, Zhao J, Wang J, Yu T, Wang J, Li N. Transgenic milk containing recombinant human lactoferrin modulates the intestinal flora in piglets. Biochem Cell Biol. 2012; 90: 485–96.
[23]	Underwood MA, Arriola J, Gerber CW, Kaveti A, Kalanetra KM, Kananurak A, et al. Bifidobacterium longum subsp. infantis in experimental necrotizing enterocolitis: alterations in inflammation, innate immune response, and the microbiota. Pediatr Res. 2014; 76: 326-33.
[24]	Edde L, Hipolito RB, Hwang FF, Headon DR, Shalwitz RA, Sherman MP. Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol. 2001; 281: G1140-50.
[25]	Akin IM, Atasay B, Dogu F, Okulu E, Arsan S, Karatas HD, et al. Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells. Am J Perinatol. 2014; 31: 1111-20.
[26]	Latorre D, Berlutti F, Valenti P, Gessani S, Puddu P. LF immunomodulatory strategies: mastering bacterial endotoxin. Biochem Cell Biol. 2012; 90: 269-78.
[27]	Spadaro M, Montone M, Arigoni M, Cantarella D, Forni G, Pericle F, et al. Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4. FASEB J. 2014; 28: 416-29.
[28]	Z Blais A, Fan C, Voisin T, Aattouri N, Dubarry M, Blachier F, et al. Effects of lactoferrin on intestinal epithelial cell growth and differentiation: an in vivo and in vitro study. Biometals. 2014; 27: 857-74.
[29]	Reznikov EA, Comstock SS, Yi C, Contractor N, Donovan SM. Dietary bovine lactoferrin increases intestinal cell proliferation in neonatal piglets. J Nutr. 2014; 144: 1401-8.
[30]	Nguyen DN, Li Y, Sangild PT, Bering SB, Chatterton DE. Effects of bovine lactoferrin on the immature porcine intestine. Br J Nutr. 2014; 111: 321-31.
[31]	Sherman MP, Bennett SH, Hwang FFY, Yu C. Neonatal small bowel epithelia: enhancing anti-bacterial defense with lactoferrin and Lactobacillus GG. Biometals. 2004; 17: 285-9.
[32]	Manzoni P, Meyer M, Stolfi I, Rinaldi M, Cattani S, Pugni L, et al. Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial. Early Hum Dev. 2014; 90: S60-5.
[33]	Seigel JK, Smith PB, Ashley PL, Cotten CM, Herbert CC, King BA, et al. Early administration of oropharyngeal colostrum to extremely low birth weight infants. Breastfeed Med. 2013; 8: 491-5.